Most men with low-grade prostate cancer have an excellent prognosis, with a five-year survival rate of more than 99%. But ...

From the foods men eat to how surgery is planned and public awareness unfolds, new research presented at the American Urological Association (AUA) Annual Meeting in Washington, DC, shows prostate ...

New research suggests that men who take multivitamins after being diagnosed with prostate cancer may have a lower risk of cancer recurrence. In the overall study group, current multivitamin users ...

Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism.

Researchers at Moffitt Cancer Center report encouraging early results from a phase 2 study examining whether immunotherapy ...

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to compare two types of targeted radiation therapy for men with recurrent prostate ...

Patients who reported current multivitamin use had a lower risk of recurrence than patients who had never taken multivitamins. Patients with prostate cancer may have a lower risk of recurrence if they ...

Non-inferior salvage treatment–free survival at 30 months favored HIFU (90%) versus salvage radical prostatectomy (86%), ...

Patients who developed biochemical recurrence had a higher PSA at diagnosis, more advanced pT stages, a higher rate of pN1 stage disease, a higher rate of R1 or Rx resection, and a higher rate of ...

Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus ...

The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...